The number of active drug shortages has declined sharply since June, according to the FDA’s database.
As of March 19, 76 drugs are in shortage, down from 194 in mid-June.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are six recent drug shortages, according to the FDA database:
- Ursodiol capsules: Strides Pharma discontinued the 300 mg presentation as a business decision April 6.
- Idelalisib tablets: Gilead Sciences discontinued 100 mg and 150 mg Zydelig tablets due to manufacturing decisions April 7.
- Fosaprepitant dimeglumine injection: Fresenius Kabi discontinued the 150 mg/5 mL formulation April 8.
- Aprepitant oral powder for suspension: Merck discontinued the 125 mg Emend formulation, with discontinuation expected around November 2026.
- Azithromycin tablets: Pfizer discontinued 500 mg and 250 mg Zithromax tablets April 9.
- Nitrofurantoin oral suspension: Amneal Pharmaceuticals discontinued the 25 mg/5 mL formulation April 10.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
